Sandoz halts pursuit of U.S. approval for rituximab biosimilarNovember 5, 2018CLLFollicular LymphomaB Cell Lymphoma
Checkpoint inhibitor plus rituximab is active in non-Hodgkin lymphomaOctober 31, 2018Follicular LymphomaB Cell Lymphoma
Line complications plague dose-adjusted EPOCH-R in non-Hodgkin lymphomaOctober 25, 2018B Cell Lymphoma
Older age predicts mortality after alloHCT in NHL, but not relapseOctober 24, 2018Follicular LymphomaB Cell Lymphoma
Ibrutinib discontinuation harms survival in CLLOctober 18, 2018CLLMantle Cell LymphomaB Cell Lymphoma
Entospletinib falls short in relapsed/refractory DLBCLOctober 11, 2018Follicular LymphomaB Cell Lymphoma
